(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.
He said: "We all kind of put our heads together and said, ‘Okay, where are we going?’ And they had a very specific plan for how they were going to treat this? "At that point, [when the test came back ...